Severe Alopecia Areata clinical trials

Explore recruiting severe alopecia areata clinical trials.

Recruiting severe alopecia areata studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Alopecia Areata trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata

Bulgaria, Romania, Poland, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Poland, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2B, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of Rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Severe Alopecia Areata

Germany, Belgium, Poland, Italy, Portugal, Croatia +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Italy, France, Czechia, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata

Italy, Netherlands, Czechia, Romania, Germany, France +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Severe Alopecia Areata trials by city

Severe Alopecia Areata in Toronto Severe Alopecia Areata in Vancouver Severe Alopecia Areata in Montreal Severe Alopecia Areata in Calgary Severe Alopecia Areata in Edmonton Severe Alopecia Areata in Ottawa Severe Alopecia Areata in Winnipeg Severe Alopecia Areata in Quebec City Severe Alopecia Areata in Hamilton Severe Alopecia Areata in Kitchener Severe Alopecia Areata in London Severe Alopecia Areata in Halifax Severe Alopecia Areata in New York Severe Alopecia Areata in Los Angeles Severe Alopecia Areata in Chicago Severe Alopecia Areata in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease